Innovative treatment eliminates need for long-term insulin

A revolutionary treatment for type 2 diabetes has emerged, offering hope to millions of patients around the world. This innovative approach combines a new procedure with medications, potentially eliminating the need for long-term insulin therapy. As diabetes continues to affect increasing numbers of people around the world, this breakthrough could revolutionize treatment strategies and improve the quality of life for countless people.

Unveiling of the revolutionary reception procedure

The cornerstone of this innovative treatment is a procedure known as Re-Cellularization by Electroporation (ReCET). This endoscopic technique aims to improve glycemic control in type 2 diabetic patients by targeting a specific area of ​​the small intestine.

ReCET works by delivering electrical pulses to remove the surface layer of the duodenum, a crucial area for digestion and sugar regulation. These impulses disrupt the cell membrane, inducing natural cell death without damaging the mucosa. The non-thermal nature of this process minimizes the risk of complications.

THE key advantage of ReCET lies in its ability to promote cellular regeneration. As the eliminated cells are replaced, new metabolically active cells emerge that are better equipped to manage blood sugar levels. This regenerative process forms the basis for better glucose regulation in diabetic patients.

In a recent clinical trial, 14 diabetic participants aged 28 to 75, all overweight or obese, underwent the ReCET procedure. The endoscopy was performed under deep sedation, ensuring patient comfort throughout the process. After the procedure, participants followed a strict liquid and isocaloric diet for two weeks, preparing their bodies for the next phase of treatment.

Combine the recipe with semaglutide for optimal results

The second step of this innovative treatment involves the administration of semaglutide, a medication used to treat both type 2 diabetes and obesity. Semaglutide mimics the action of GLP-1, a natural hormone that plays a crucial role in regulating blood sugar levels.

Although semaglutide can cause gastrointestinal side effects in some patients, the majority of trial participants tolerated the treatment well. Only one person experienced nausea after reaching the maximum intended dose of 1 mg per week.

THE synergistic effect of ReCET and semaglutide proved remarkable. One year after the trial, a staggering 86% of participants no longer needed insulin to maintain stable blood sugar levels. In addition, their glycated hemoglobin (HbA1c) level, a key indicator of glycemic control, remained below 7.5%. According to the French Diabetes Federation, a rate equal to or less than 7% is considered indicative of well-controlled diabetes.

Perhaps most encouraging is the longevity of these results. The positive changes observed in participants persisted throughout the 24-month follow-up period, suggesting a lasting impact of the treatment.

Fighting the global diabetes epidemic

The World Health Organization (WHO) reports that diabetes affects a staggering 422 million people worldwide, with type 2 diabetes being the most common form among adults. This global health crisis is expanding at an alarming rate, fueled by various risk factors:

• Sedentary lifestyles
• Genetic predisposition
• Unhealthy habits
• Obesity (a main contributor)

Traditionally, insulin therapy is prescribed to help regulate blood sugar levels in diabetic patients. However, administering insulin can cause significant side effects, including weight gain. This creates a vicious cycle, as excess weight promotes insulin resistance, further complicating diabetes management.

The development of alternative treatments such as the ReCET procedure and the semaglutide combination responds head-on to these challenges. By potentially eliminating the need for insulin injections, this innovative approach could break the cycle of weight gain and insulin resistance that affects many diabetic patients.

This advance in diabetes treatment aligns with other recent medical advances, such as the revolutionary blood test that detects cancers before symptoms appear, demonstrating rapid advances in medical diagnostics and treatments.

Promising results and future implications

Dr. Céline Bush, who led the study, presented these results during UEG Week, a prestigious gastroenterology conference. The research has since been published in the journal Gastrointestinal Endoscopy (GIE), confirming its importance in the medical community.

Bush expressed optimism about the results, saying, “These results are very encouraging and suggest that ReCET is a safe and feasible procedure that, when combined with semaglutide, can effectively eliminate the need for insulin therapy.” »

The potential impact of this treatment extends beyond individual patient care. By reducing or eliminating the need for long-term insulin use, it could significantly reduce healthcare costs associated with diabetes management. Furthermore, improving patients’ quality of life by freeing them from daily insulin injections represents a major advance in the management of diabetes.

As research advances in this area, it could open the door to new treatment modalities for other metabolic disorders. The success of combining minimally invasive procedures with targeted drugs could inspire similar approaches in the treatment of various chronic diseases.

This innovative diabetes treatment joins other groundbreaking medical discoveries, such as the FDA-approved antidepressant showing promise in treating incurable brain cancer, highlighting the diverse and rapid advances in medical science.

As this innovative treatment for type 2 diabetes continues to be studied and refined, it promises to transform diabetes management globally. By addressing the root causes of insulin resistance and providing a long-term solution, this breakthrough could significantly improve the lives of millions of people with diabetes.